深圳市海普瑞药业股份有限公司 2015 年半年度报告全文 深圳市海普瑞药业股份有限公司 2015 年半年度报告 2015 年 08 月 1 深圳市海普瑞药业股份有限公司 2015 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人李锂、主管会计工作负责人孔芸及会计机构负责人(会计主管人 员)孔芸声明：保证本半年度报告中财务报告的真实、准确、完整。 2 | 目录 | | --- | | 2015 | 半年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 5 | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 27 | | 第五节 | 重要事项 37 | | 第六节 | 股份变动及股东情况 40 | | 第七节 | 优先股相关情况 40 | | 第八节 | 董事、 ...

深圳市海普瑞药业股份有限公司 2015 年第一季度报告正文 证券代码：002399 证券简称：海普瑞 公告编号：2015-032 深圳市海普瑞药业股份有限公司 2015 年第一季度报告正文 1 深圳市海普瑞药业股份有限公司 2015 年第一季度报告正文 2 深圳市海普瑞药业股份有限公司 2015 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 740,707,835.43 | 312,624,951.37 | 136.93% | | 归属于上市公司股东的净利润（元） | 185,310,020.02 | 70,985,141.09 | 161.05% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 175,203,495.04 | 69,927,084.88 | 150.55% | | 经营活动产生的现金流量净额（元） | 257,033 ...

深圳市海普瑞药业股份有限公司 2014 年年度报告全文 深圳市海普瑞药业股份有限公司 2014 年年度报告 2015 年 04 月 1 深圳市海普瑞药业股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司经本次董事会审议通过的利润分配预案为：以 2014 年 12 月 31 日的公 司总股本为基数，向全体股东每 10 股派发现金红利 3.00 元（含税），送红股 0 股（含税），不以公积金转增股本。 公司负责人李锂、主管会计工作负责人孔芸及会计机构负责人(会计主管人 员)孔芸声明：保证年度报告中财务报告的真实、准确、完整。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实际性承诺，敬请投资者注意投资风险。 2 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 单宇 董事 工作原因 步海华 | 2014 | 年度报告 2 | | ...

深圳市海普瑞药业股份有限公司 2014 年第三季度报告正文 证券代码：002399 证券简称：海普瑞 公告编号：2014-071 深圳市海普瑞药业股份有限公司 2014 年第三季度报告正文 1 深圳市海普瑞药业股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李锂、主管会计工作负责人孔芸及会计机构负责人(会计主管人员)孔芸声明：保证季度报 告中财务报表的真实、准确、完整。 2 深圳市海普瑞药业股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 9,549,464,315.08 | 8,271,379,2 ...

深圳市海普瑞药业股份有限公司 2014 年半年度报告全文 深圳市海普瑞药业股份有限公司 2014 年半年度报告 2014 年 08 月 1 深圳市海普瑞药业股份有限公司 2014 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人李锂、主管会计工作负责人孔芸及会计机构负责人(会计主管人 员)孔芸声明：保证本半年度报告中财务报告的真实、准确、完整。 本报告中如涉及未来计划等前瞻性陈述，不构成公司对投资者的实质性承 诺，请投资者注意投资风险。 2 | 2014 | 半年度报告 2 | | --- | --- | | 第一节 | 重要提示、目录和释义 5 | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 26 | | 第五节 | 重要事项 36 | | 第六节 | 股份变动及股东情况 39 | ...

Financial Performance - The company's revenue for Q1 2014 was ¥312,624,951.37, a decrease of 30.63% compared to ¥450,657,197.79 in the same period last year[6] - Net profit attributable to shareholders was ¥70,985,141.09, down 48.97% from ¥139,102,767.21 year-on-year[6] - Basic and diluted earnings per share were both ¥0.09, a decline of 47.06% from ¥0.17 in the same period last year[6] - Operating revenue decreased by 30.63% compared to the same period last year, mainly due to a decline in both sales volume and sales price[15] - Net profit attributable to the parent company decreased by 48.97%, as the decline in operating revenue was greater than the decline in operating costs[16] - The net profit attributable to shareholders for the first half of 2014 is expected to decline by 65% to 45%, ranging from 87.593 million to 137.646 million RMB[24] - The net profit for the first half of 2013 was 250.2657 million RMB, indicating a significant decrease in performance year-over-year[24] - The decline in performance is primarily due to a decrease in the sales price of heparin sodium raw materials compared to the same period last year[24] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 188.29%, reaching ¥140,766,096.16 compared to ¥48,828,624.18 in the previous year[6] - Cash flow from operating activities increased by 188.29% compared to the same period last year, mainly due to reduced payments for raw material purchases[18] - Cash flow from investing activities decreased by 99.68%, primarily due to increased net cash inflow from bank wealth management products and the absence of large investment expenditures compared to the previous year[18] - Cash and cash equivalents increased by 163.33% compared to the same period last year, driven by changes in investment and financing activities[18] - Total assets at the end of the reporting period were ¥8,356,835,748.37, reflecting a 1.03% increase from ¥8,271,379,204.50 at the end of the previous year[6] - Net assets attributable to shareholders increased by 1.56% to ¥8,110,641,271.76 from ¥7,986,056,392.22 at the end of the previous year[6] Shareholder Information - The total number of shareholders at the end of the reporting period was 36,198[9] - The top shareholder, Shenzhen Le Ren Technology Co., Ltd., held 36.94% of the shares, amounting to 295,562,100 shares[9] - Shareholder Zhuang Xiuchun conducted a repurchase transaction involving 1,464,000 shares, representing 0.18% of the total share capital[10] Changes in Financial Position - Trading financial assets decreased by 100% at the end of the reporting period due to the expiration and settlement of forward foreign exchange contracts[13] - Prepayments increased by 65.27% at the end of the reporting period, primarily due to increased advance payments for raw material purchases[13] - Accounts payable decreased by 43.73% at the end of the reporting period, mainly due to payments made for engineering equipment[14] - Other receivables decreased by 74.35% at the end of the reporting period, primarily due to a reduction in receivables for export tax rebates[13] Investments - The company invested 9,999,999 USD to acquire 48,147,053 shares of Prometic Life Sciences Inc., representing 10.02% of the enlarged share capital[25] - The purchase cost for the shares in Prometic Life Sciences Inc. was 62,160,000 RMB, with a fair value change amounting to 256,875,709.91 RMB as of March 31, 2014[26] - As of April 21, 2014, the company's shareholding in Prometic Life Sciences Inc. decreased to 9.11% due to an increase in the total number of issued shares[26] Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥1,058,056.21 for the period[7] Consolidation Impact - The consolidation of SPL Acquisition Corp into the financial statements starting April 2014 has led to substantial intermediary and financing costs, negatively impacting operating performance[24]

Financial Performance - The company's operating revenue for 2013 was ¥1,513,168,624.17, a decrease of 14.11% compared to ¥1,761,820,027.92 in 2012[21] - The net profit attributable to shareholders for 2013 was ¥317,334,752.99, down 49.18% from ¥624,393,334.37 in 2012[21] - The net profit after deducting non-recurring gains and losses was ¥313,986,311.66, a decrease of 49.66% compared to ¥623,785,454.51 in 2012[21] - The net cash flow from operating activities was ¥420,968,576.32, down 11.17% from ¥473,890,043.41 in 2012[21] - Basic earnings per share for 2013 were ¥0.4, a decline of 48.72% from ¥0.78 in 2012[21] - The company's operating revenue for 2013 was CNY 1,513.17 million, a decrease of 14.11% compared to the previous year[33] - The main business income was CNY 1,512.36 million, down 14.15% year-on-year, primarily due to an 8.24% decrease in the price of heparin sodium raw materials and a 7.42% decline in sales volume[38] - In 2013, the company's total revenue was CNY 1,512,357,201.71, a decrease of 14.15% compared to 2012[53] - The cost of goods sold was CNY 1,135,515,040.70, resulting in a gross margin of 24.92%, which is a decrease of 3.75% year-over-year[53] - R&D expenses increased by 32.85% to CNY 39,972,200, accounting for 2.64% of total revenue, up from 1.71% in 2012[48] Assets and Liabilities - The total assets at the end of 2013 were ¥8,271,379,204.50, an increase of 0.14% from ¥8,259,893,243.21 at the end of 2012[21] - The net assets attributable to shareholders at the end of 2013 were ¥7,986,056,392.22, up 0.31% from ¥7,961,506,212.56 at the end of 2012[21] - As of the end of 2013, cash and cash equivalents amounted to ¥6,050,275,614.08, representing 73.15% of total assets, a decrease of 6.61% compared to the end of 2012[55] - Accounts receivable decreased to ¥196,025,543.07, accounting for 2.37% of total assets, down by 1.91% from the previous year[55] - Inventory increased to ¥677,466,001.34, which is 8.19% of total assets, reflecting a rise of 1.55% year-over-year[55] Investments and Acquisitions - The company completed the construction and production of a project with an annual capacity of 50 trillion units of heparin sodium raw materials, increasing the designed capacity to 100 trillion units[35] - The company acquired 100% of SPL's equity, enhancing its competitive advantage in the heparin raw material industry[32] - The company invested ¥262,160,000.00 during the reporting period, a 52.4% increase compared to ¥172,016,060.00 in the previous year[62] - The company has made significant investments in equity stakes and joint ventures, including a 36% stake in Chengdu Haitong Pharmaceutical Co., Ltd. and a 24% stake in Chengdu Shenrui Livestock Products Co., Ltd.[81] - The company plans to acquire SPL Acquisition Corp. through its wholly-owned subsidiary HEPALINK USA INC. for a cash payment, with contingent payments related to the commercialization of enzyme products totaling up to $87.5 million depending on FDA approval timelines[136] Research and Development - The company implemented 18 R&D projects during the reporting period, completing 12 of them, focusing on the quality and process of heparin sodium products[35] - Continuous R&D efforts are being made in process technology and new product specifications to maintain a competitive edge in the heparin sodium raw material market[123] - The company plans to invest in R&D to maintain its competitive edge in heparin raw material production and develop new drug candidates[103] Risk Management - The company has highlighted potential risks including product price declines, cost increases, and integration challenges related to acquisitions[12] - The company faces risks from potential price declines in heparin products due to increased competition and rising production costs, which could adversely affect its financial performance[105] - The company emphasizes quality control and safety training to mitigate risks associated with product quality and safety in production[106] Shareholder Returns - The company plans to distribute a cash dividend of ¥3 per 10 shares to all shareholders based on the total share capital as of December 31, 2013[5] - The company achieved a net profit of 385,677,084.57 RMB for the year 2013, with 10% allocated to statutory reserves, amounting to 38,567,708.46 RMB[117] - The cash dividend for 2013 is set at CNY 240,060,000, representing 100% of the total profit distribution[120] - The company has maintained a cash dividend policy, distributing more than 30% of the average distributable profit over the past three years[114] - The cash dividend payout ratio over the past three years has exceeded 70% of the net profit attributable to shareholders[121] Corporate Governance and Compliance - The company has established a robust governance structure to protect the rights of shareholders and creditors, ensuring timely and accurate information disclosure[121] - The company has not faced any administrative penalties during the reporting period, indicating compliance with regulatory standards[124] - The company has not reported any significant changes in project feasibility or major issues regarding the use of raised funds[83] Market Position and Strategy - The global heparin market is expected to continue expanding due to increased clinical applications and a growing patient population, despite recent price declines in heparin sodium raw materials[97] - China's heparin raw material supply accounts for over 50% of the global supply, with exports to 46 countries in 2013, where the top five markets (France, Germany, the USA, Italy, and India) accounted for 73% of total exports[100] - The company plans to enhance production capacity and efficiency in 2014, focusing on the integration of acquired businesses and optimizing internal structures[102] - The company is committed to expanding its market presence in emerging markets like India and Russia while leveraging synergies from recent acquisitions[103] Subsidiaries and Operations - The company has a total of 12 subsidiaries, including Shenzhen Duopusheng Biotechnology Co., Ltd. and Shenzhen Beidiao Technology Development Co., Ltd., focusing on heparin raw material production and biopharmaceutical technology development[89][90] - The company’s subsidiary, Shenzhen Junshengtai Biotechnology Co., Ltd., focuses on the research and development of peptide bioproducts, with a registered capital of RMB 35 million[90] - The company’s subsidiary, Shenzhen Pingshan New District Hepalink Pharmaceutical Co., Ltd., is engaged in the production of small-volume injections and is currently in the preparatory stage[91] Financial Audit and Reporting - The company appointed Ruihua Certified Public Accountants as the financial audit institution for the 2013 fiscal year, with an audit fee of 1.04 million yuan[170] - The company has maintained a continuous relationship with Ruihua Certified Public Accountants for auditing services since the merger of its previous auditor[171] - The company has not reported any violations or penalties involving its directors, supervisors, or senior management during the reporting period[173]